There have been no open-market insider trades at Checkpoint Therapeutics, Inc. in the last 12 months.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
There have been no open-market insider trades at Checkpoint Therapeutics, Inc. in the last 12 months.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | Fortress Biotech, Inc. | 10% Owner | Sell | 100,000 | $1.29 | $129K | SEC |
| Apr 3, 2025 | Oliviero James F III | CEO | Sell | 15,090 | $4.04 | $61K | SEC |
| Apr 3, 2025 | GRAY WILLIAM GARRETT | CFO | Sell | 12,322 | $4.05 | $50K | SEC |
| Feb 11, 2025 | Oliviero James F III | CEO | Sell | 10,331 | $3.15 | $33K | SEC |
| Feb 11, 2025 | Oliviero James F III | CEO | Sell | 9,233 | $3.41 | $31K | SEC |
| Feb 7, 2025 | GRAY WILLIAM GARRETT | CFO | Sell | 74,110 | $3.67 | $272K | SEC |
| Dec 20, 2024 | Oliviero James F III | CEO | Sell | 220,230 | $3.38 | $744K | SEC |
| Dec 20, 2024 | Oliviero James F III | CEO | Sell | 602,167 | $3.87 | $2.3M | SEC |
| Dec 20, 2024 | GRAY WILLIAM GARRETT | CFO | Sell | 268,432 | $4.01 | $1.1M | SEC |
| Jun 28, 2024 | Oliviero James F III | CEO | Sell | 24,610 | $2.05 | $50K | SEC |
| Jun 28, 2024 | GRAY WILLIAM GARRETT | CFO | Sell | 13,038 | $2.06 | $27K | SEC |
| Mar 1, 2024 | Oliviero James F III | CEO | Sell | 5,894 | $2.06 | $12K | SEC |
| Mar 1, 2024 | GRAY WILLIAM GARRETT | CFO | Sell | 2,035 | $2.07 | $4K | SEC |
| Feb 2, 2024 | GRAY WILLIAM GARRETT | CFO | Sell | 4,115 | $1.95 | $8K | SEC |
| Feb 2, 2024 | Oliviero James F III | CEO | Sell | 11,900 | $2.01 | $24K | SEC |
There were no open-market insider trades in CKPT in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
No congressional trades in CKPT were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).